Gilead Sciences, Inc. (GILD) 肿瘤药物 Trodelvy - Trodelvy 在治疗转移性或晚期 NSCLC 患者的研究未达到主要终点——总生存期（OS），尽管在具有鳞状和非鳞状组织学的患者中观察到了有利于 sacituzumab govitecan 的 OS 的数值改善[3] - Trodelvy 在治疗乳腺癌和膀胱癌等多种癌症方面获得了批准，并且自获批以来表现出色，推动了 Gilead 在肿瘤领域的发展[6][7][8] - Gilead 目前正在进行多项注册阶段 III 研究和几项阶段 II 研究，评估 Trodelvy 在 NSCLC 指标中的表现，同时也在肺癌领域进行广泛的临床开发计划[12][13][14] ADCs 和肿瘤疗法 - ADCs 在制药/生物技术行业备受关注，AbbVie Inc.（ABBV）宣布将收购 ImmunoGen, Inc.（IMGN），加入 Immunogen 的癌症疗法 Elahere 到其产品组合中[16][17] 股票评级和盈利预期 - Gilead 目前的 Zacks Rank 为 3（持有），而在生物技术领域中，Regeneron Pharmaceuticals（REGN）的 Zacks Rank 为 1（强烈推荐买入）[18][19] - Regeneron Pharmaceuticals（REGN）的 2024 年盈利预期上调，股价在过去一年中上涨了 29.6%，并且连续四个季度超出预期，平均盈利惊喜率为 12.34%[20]

Pharmaceutical sector mainstay Gilead Sciences (GILD -10.15%) has had many good days on the stock exchange, but Monday wasn't one of them. On the back of dispiriting clinical trial results for one of its investigational medications, investors sent the company's share price down by more than 10%. And that was on a day when the bellwether S&P 500 index ended in positive territory, rising almost 0.3%.Trodelvy didn't meet its latest primary endpointThat trial was a late-stage one for Trodelvy, an approved cance ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

Shares of Gilead fell more than 9% on Monday after a key drug from the company did not significantly extend the lives of patients with a certain lung cancer in a late-stage trial.The results are a blow to Gilead, which is working to become a power player in the cancer space. The treatment, Trodelvy, is one of Gilead's best-selling cancer drugs, contributing roughly a third of its $769 million in oncology sales during the third quarter.The phase-three study is part of an effort to expand the use of Trodelvy, ...

Gilead Sciences Inc (NASDAQ: GILD) says its drug conjugate Trodelvy disappointed in a late-stage cancer trial. Shares of the biotech firm opened about 10% down today.Trodelvy failed to meet primary endpointCopy link to sectionTrodelvy did not meet the “primary endpoint of overall survival in previously treated metastatic non-small cell lung cancer”. EVOKE-01 – the aforementioned phase three trial evaluated the drug conjugate versus docetaxel, as per a press release on Monday.The news arrives only days befor ...

Shares of Gilead Sciences Inc. GILD, +1.03% tumbled 10.9% beating in premarket trading Monday, to pullback from an 11-month high, after the biotechnology company disappointing trial results of its lung cancer treatment. That selloff would put the stock in danger of the biggest one-day decline since it plunged 14.3% on Dec. 22, 2014. The company said the Phase 3 Evoke-01 study of Trodelvy vs. docetaxel did not meet its primary endpoint of overall survival in previously treated metastatic non-small cell lung ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC). EVOKE-01 is evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) vs. docetaxel in patients with metastatic or advanced NSCLC that had progressed on or after platinum-based chemotherapy and checkpoint inhibitor therapy. A numerical improvement in OS favoring S ...

股价表现 - Gilead Sciences (GILD) 最近的股价为 $86.48，较前一天上涨了 +0.57%。该股超过了标普500指数的日损失0.56%。同时，道琼斯指数下跌了0.25%，科技股重要指数纳斯达克下跌了0.59%[1] - 过去一个月，HIV和丙型肝炎药物制造商的股价上涨了8.18%，超过了医疗行业的3.8%和标普500指数的1.2%的表现[2] 财报预测 - 公司的财报将于2024年2月6日公开。预计公司将发布每股收益为$1.77，较去年同期增长5.99%。同时，Zacks对营收的预测显示净销售额为$70.7亿，较去年同期下降4.25%[3] 分析师预测修订 - 投资者还应关注分析师对Gilead Sciences的最新预测修订。这些修订有助于展示近期业务趋势的不断变化。因此，预测的乐观变化表明分析师对公司的业务健康和盈利能力持有积极看法[4]

In a downtown Toronto skyscraper one block away from the Hockey Hall of Fame, a small hedge fund is hoping it has found an edge in financial markets. Castle Ridge Asset Management is betting on Wallace, a purpose-built supercomputer behind the hedge fund’s trading strategies driven by artificial intelligence.For years, hedge-fund players have wondered if AI could help them beat the market, but AI-trading efforts they launched often led to disappointment and amounted to little more than marketing schemes to ...

The latest trading session saw Gilead Sciences (GILD) ending at $85.39, denoting a +1.05% adjustment from its last day's close. The stock exceeded the S&P 500, which registered a loss of 0.07% for the day.Shares of the HIV and hepatitis C drugmaker witnessed a gain of 1.7% over the previous month, trailing the performance of the Medical sector with its gain of 7.37% and the S&P 500's gain of 3.98%.Investors will be eagerly watching for the performance of Gilead Sciences in its upcoming earnings disclosure. ...